Cargando…

Response to: The BRAIN TRIAL: a randomized, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury - authors' reply

A response to the letter regarding The BRAIN TRIAL: a randomized, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury, by Mr Vincent Simmon President and CEO of Xytis Inc.

Detalles Bibliográficos
Autores principales:	Roberts, Ian, Shakur, Haleema
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2797008/ http://dx.doi.org/10.1186/1745-6215-10-111

Ejemplares similares

The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury
por: Shakur, Haleema, et al.
Publicado: (2009)

Response to: The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury
por: Simmon, Vincent F
Publicado: (2009)

CRASH-3 - tranexamic acid for the treatment of significant traumatic brain injury: study protocol for an international randomized, double-blind, placebo-controlled trial
por: Dewan, Yashbir, et al.
Publicado: (2012)

A nested mechanistic sub-study into the effect of tranexamic acid versus placebo on intracranial haemorrhage and cerebral ischaemia in isolated traumatic brain injury: study protocol for a randomised controlled trial (CRASH-3 Trial Intracranial Bleeding Mechanistic Sub-Study [CRASH-3 IBMS])
por: Mahmood, Abda, et al.
Publicado: (2017)

A nested randomised trial of the effect of tranexamic acid on intracranial haemorrhage and infarction in traumatic brain injury (CRASH-3 trial intracranial bleeding mechanistic study): Statistical analysis plan
por: Mahmood, Abda, et al.
Publicado: (2019)

Tranexamic acid for significant traumatic brain injury (The CRASH-3 trial): Statistical analysis plan for an international, randomised, double-blind, placebo-controlled trial
por: Roberts, Ian, et al.
Publicado: (2018)

Use of the Oxford Handicap Scale at hospital discharge to predict Glasgow Outcome Scale at 6 months in patients with traumatic brain injury
por: Perel, Pablo, et al.
Publicado: (2008)

Cost-effectiveness analysis of tranexamic acid for the treatment of traumatic brain injury, based on the results of the CRASH-3 randomised trial: a decision modelling approach
por: Williams, Jack, et al.
Publicado: (2020)

A cost-effectiveness and value of information analysis to inform future research of tranexamic acid for older adults experiencing mild traumatic brain injury
por: Williams, Jack, et al.
Publicado: (2022)

The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial
por: Shakur, Haleema, et al.
Publicado: (2010)

Antifibrinolytic Agents in Traumatic Haemorrhage
por: Coats, Tim, et al.
Publicado: (2005)

Risk factors for blood transfusion in traumatic and postpartum hemorrhage patients: Analysis of the CRASH-2 and WOMAN trials
por: Kolin, David A., et al.
Publicado: (2020)

Tranexamic acid for the prevention of postpartum bleeding in women with anaemia: Statistical analysis plan for the WOMAN-2 trial: an international, randomised, placebo-controlled trial
por: Collier, Tim, et al.
Publicado: (2023)

Accuracy of time to treatment estimates in the CRASH-3 clinical trial: impact on the trial results
por: Mansukhani, Raoul, et al.
Publicado: (2020)

Statistical analysis plan for the Erythropoietin in Traumatic Brain Injury trial: a randomised controlled trial of erythropoietin versus placebo in moderate and severe traumatic brain injury
por: Presneill, Jeffrey, et al.
Publicado: (2014)

No effect of tranexamic acid on platelet function and thrombin generation (ETAPlaT) in postpartum haemorrhage: a randomised placebo-controlled trial
por: Dallaku, Kastriot, et al.
Publicado: (2019)

Interleukin-1 Receptor Antagonist as Therapy for Traumatic Brain Injury
por: Lindblad, Caroline, et al.
Publicado: (2023)

Effect of tranexamic acid on intracranial haemorrhage and infarction in patients with traumatic brain injury: a pre-planned substudy in a sample of CRASH-3 trial patients
por: Mahmood, Abda, et al.
Publicado: (2021)

Tranexamic acid for treatment of women with post-partum haemorrhage in Nigeria and Pakistan: a cost-effectiveness analysis of data from the WOMAN trial
por: Li, Bernadette, et al.
Publicado: (2018)

Effect of tranexamic acid on mortality in patients with traumatic bleeding: prespecified analysis of data from randomised controlled trial
por: Roberts, Ian, et al.
Publicado: (2012)

164 Treatment of Acquired Angioedema with the Bradykinin Receptor Antagonist Icatibant
por: Siani, Maria Concetta, et al.
Publicado: (2012)

Cost-Effectiveness Analysis of Administering Tranexamic Acid to Bleeding Trauma Patients Using Evidence from the CRASH-2 Trial
por: Guerriero, Carla, et al.
Publicado: (2011)

Managing clinical trials
por: Farrell, Barbara, et al.
Publicado: (2010)

The added value of ordinal analysis in clinical trials: an example in traumatic brain injury
por: Roozenbeek, Bob, et al.
Publicado: (2011)

Current Clinical Trials in Traumatic Brain Injury
por: Ahmed, Zubair
Publicado: (2022)

Tranexamic acid by the intramuscular or intravenous route for the prevention of postpartum haemorrhage in women at increased risk: a randomised placebo-controlled trial (I’M WOMAN)
por: Brenner, Amy, et al.
Publicado: (2023)

Tranexamic acid for patients with traumatic brain injury: a randomized, double-blinded, placebo-controlled trial
por: Yutthakasemsunt, Surakrant, et al.
Publicado: (2013)

Risperidone versus placebo for aggression following traumatic brain injury: a feasibility randomised controlled trial
por: Deb, Shoumitro, et al.
Publicado: (2020)

European society of intensive care medicine study of therapeutic hypothermia (32-35°C) for intracranial pressure reduction after traumatic brain injury (the Eurotherm3235Trial)
por: Andrews, Peter JD, et al.
Publicado: (2011)

Voltage-Gated Calcium Channel Antagonists and Traumatic Brain Injury
por: Gurkoff, Gene, et al.
Publicado: (2013)

Molecular Features of Non-Selective Small Molecule Antagonists of the Bradykinin Receptors
por: Rasaeifar, Bahareh, et al.
Publicado: (2020)

The effect of tranexamic acid on the risk of death and hysterectomy in women with post-partum haemorrhage: statistical analysis plan for the WOMAN trial
por: Shakur, Haleema, et al.
Publicado: (2016)

Risk factors for peripartum hysterectomy among women with postpartum haemorrhage: analysis of data from the WOMAN trial
por: Huque, Sumaya, et al.
Publicado: (2018)

Trial management: we need a cadre of high-class triallists to deliver the answers that patients need
por: Beaumont, Danielle, et al.
Publicado: (2019)

Another trial for the TARGET trial. Author’s reply
por: Hagel, Stefan, et al.
Publicado: (2022)

Effect of Bradykinin Postconditioning on Ischemic and Toxic Brain Damage
por: Lalkovičová, Mária, et al.
Publicado: (2015)

The impact of early outcome events on the effect of tranexamic acid in post-partum haemorrhage: an exploratory subgroup analysis of the WOMAN trial
por: Brenner, Amy, et al.
Publicado: (2018)

Tranexamic acid for the prevention of postpartum bleeding in women with anaemia: study protocol for an international, randomised, double-blind, placebo-controlled trial
por: Ker, Katharine, et al.
Publicado: (2018)

Tranexamic acid for acute gastrointestinal bleeding (the HALT-IT trial): statistical analysis plan for an international, randomised, double-blind, placebo-controlled trial
por: Brenner, Amy, et al.
Publicado: (2019)

Avoidable mortality from giving tranexamic acid to bleeding trauma patients: an estimation based on WHO mortality data, a systematic literature review and data from the CRASH-2 trial
por: Ker, Katharine, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_cj1pv572epqfaun68kq42qcn6a